IMPORTANCE Lung cancer is the leading cause of cancer-related mortality in the United States and worldwide. As systemic therapies improve, patients with lung cancer live longer and thus are at increased risk for brain metastases. Understanding how prognosis varies across this heterogeneous patient population is essential to individualize care and design future clinical trials.
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Supplemental content
Author Affiliations: Author affiliations are listed at the end of this article. W orldwide, in 2012, there were an estimated 1.24 million new lung cancers and 1.1 million lung cancerrelated deaths. 1 In 2016, in the United States alone, an estimated 224 000 new patients will be diagnosed with lung cancer, and over 158 000 will die from the disease. 2 One of the most frequent and serious complications of this ubiquitous disease is metastasis to the brain, for which lung cancer remains the most common cause. Although there are no global or national population-based estimates on the true incidence of brain metastases, conservative estimates are that 10% to 30% of patients with lung cancer will develop brain metastases.
3
In the past, survival after the development of brain metastases was poor and treatment often considered futile. 4 With the recent advent of molecularly targeted therapies 5,6 and immunotherapies, 7, 8 survival from lung cancer continues to improve. Patients are thus at greater risk for developing late sequelae of the disease, such as brain metastases. These trends coupled with the wide availability of magnetic resonance imaging suggest there will be an increasing number of patients diagnosed with brain metastases in coming years. Extensive efforts have focused on predicting outcomes for the extremely heterogeneous population of patients who develop brain metastases. Data from 1200 patients in 3 clinical trials performed by the Radiation Therapy Oncology Group (RTOG) were used to generate the Recursive Partitioning Analysis (RPA). 9 The RPA is a prognostic index using patient age, Karnofsky Performance Status (KPS), control of primary tumor, and extracranial metastases to define 3 classes of disease with median survival ranging from 2.3 to 7.1 months. 9 More recently, data from a retrospective database of 3940 patients was used to design the DiagnosisSpecific Graded Prognostic Assessment (DS-GPA) (available free at BrainMetGPA.com). 10 A series of GPA studies have
shown that survival and the factors that predict survival vary widely by diagnosis. For lung cancer with brain metastases, the prognostic factors significant for survival were age, KPS, extracranial metastases, and the number of brain metastases. Four classes of disease were defined, with median survival ranging from 3.0 to 14.8 months.
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Our group has recently published a study on the effect of gene alterations on survival in patients with lung cancer and brain metastases that was based on a multi-institutional retrospective database. 11 That study showed that patients with EGFR and ALK alterations have a markedly improved survival vs those without the alterations. The purpose of the present study was to update the original DS-GPA with these molecular data to create the new Lung-molGPA.
Methods
This study was approved by the institutional review board of each participating institution. All participants provided their written informed consent. A multi-institutional retrospective database was created, including 2186 patients with NSCLC (1521 adenocarcinoma and 665 nonadenocarcinoma) and newly diagnosed brain metastases between 2006 and 2014. Variables considered included the 4 used by the existing DS-GPA (patient age, KPS, extracranial metastases, and the number of brain metastases) plus gene mutation status (EGFR, ALK,orKRAS positive), pack-years of tobacco use, sex, race, histopathologic grade, and total volume of brain metastases. Type of treatment was not considered because the purpose of a prognostic index is to estimate survival prior to treatment. Nonetheless, the treatment breakdown for the 1521 patients with lung adenocarcinoma was 50% stereotactic radiosurgery (SRS) alone; 22% whole-brain radiotherapy (WBRT); 9% WBRT + SRS; 7% surgery + SRS; 5% surgery + WBRT; and 1% surgery + WBRT + SRS.
Multiple Cox regression was used to initially select and weight variables to be included in the new Lung-molGPA. The primary end point was overall survival measured from start of brain metastasis treatment. Continuous variables were categorized to assess potential nonlinear effects. Both effect magnitude (hazard ratio [HR] ) and statistical significance were used to select variables. The final index was chosen on the basis of separation of prognostic classes with respect to overall survival, distribution of patients, and simplicity. Log-rank tests were used to compare adjacent classes as well as to compare overall survival for adenocarcinoma vs nonadenocarcinoma groups.
Results
The participant characteristics have been previously published. 11 The multivariable model used to select and weight factors in the Lung-molGPA is summarized in eTable 1 in the Supplement. Table 1 details the median survival by DS-GPA score in the original study ) and in the current study (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) for patients with NSCLC and brain metastases. In the current study, the overall median survival rates for adenocarcinoma (15.2 months) and nonadenocarcinoma (9.2 months) were significantly different (P < .001).
Adenocarcinoma
Patient age, KPS, presence of extracranial metastases, and number of brain metastases were again confirmed to be prognostic. Positive findings for EGFR and ALK were also independently prognostic and were added to the Lung-molGPA. Factors with larger effect sizes were given a maximum score of 1.0, with
Key Points
Question What is the effect of molecular alterations on survival of patients with non-small-cell lung cancer and brain metastases?
Findings In this database analysis, in addition to previously known prognostic factors, EGFR and ALK gene alterations of the original primary lung tumor were found to be associated with survival. This association has been incorporated into an updated prognostic index (Lung-molGPA).
Meaning Survival and the ability to predict survival for this population has improved significantly, and the Lung-molGPA may help facilitate clinical decision making and appropriate stratification of future clinical trials.
higher scores corresponding to better prognosis. These included KPS from 90 to 100 (HR, 0.6 vs KPS ≤70), no extracranial metastases (HR, 0.5), and EGFR or ALK positivity (HR, 0.5 vs EGFR and ALK negativity or unknown). The remaining 2 factors, age and number of brain metastases, had smaller effect sizes (HR, 0.7 and 0.8, respectively) and were given a maximum score of 0.5. Thus, the maximum score remained 4.0; the parameters of the new Lung-molGPA are detailed in Table 2 . Survival rates by the 4 prognostic classes are detailed in Table 1 and illustrated in the Figure. Only 4% of participants had Lung-molGPA scores of 3.5 to 4.0 (n = 65); however, this group had median survival of nearly 4 years. All adjacent classes had Abbreviations: DS, diagnosis-specific; GPA, graded prognostic assessment; MS, median survival; NSCLC, non-small-cell lung cancer.
a The Lung-molGPA is the updated DS-GPA designed from the data in the present study. significantly different hazard functions (unadjusted P = .03 for 1vs2;P <.001for2vs3;andP <.001for3vs4).
Nonadenocarcinoma
The 4 original variables were confirmed to be prognostic in the nonadenocarcinoma cohort. Mutation status was not routinely tested in this cohort and therefore not a part of this analysis. Although HRs suggested slightly different optimal cutoffs for age and number of brain metastases compared with adenocarcinoma, these differences did not produce a substantially better prognostic index. Therefore, we retained the same variable weighting for the 2 cohorts, although nonadenocarcinoma had a maximum score of 3.0, since patients could not receive a point for EGFR or ALK positivity. Overall survival was lower for the 3 classes relative to adenocarcinoma, as detailed in Table 1 . All adjacent classes had significantly different hazard functions (unadjusted P < .001for1vs2;andP =.04 for2vs3).
Discussion
Survival for patients with brain metastases has improved over the past 2 decades. In our updated Lung-molGPA, median survival now ranges from 3.0 to 46.8 months. The DS-GPA has unveiled nuances in management not previously appreciated: (1) recent secondary analyses applying the DS-GPA to landmark randomized trials showed that patients with good DS-PGA prognosis (score >3) achieved a survival benefit with the addition of WBRT to SRS 12,13 contrary to the current clinical trend to avoid WBRT; (2) The survival benefit of ALK alterations found by the Lung-molGPA has been reported by others 14 ; and (3) contrary to the findings of a study that did not use the DS-GPA, 15 the number of brain metastases is a prognostic factor in terms of survival. Accurate prognosis is a vital factor to inform patients, their families, and their physicians when making often difficult cancer treatment decisions.
Limitations the study has some limitations. The data are retrospective with inherent selection bias, so they cannot be used to conclude that one treatment is better than another. Also, the type, timing, combination, and sequence of chemotherapy and targeted therapies, both before and after the diagnosis of brain metastases, varied widely thus precluding the ability to assess the effect of these agents on the study patients.
Conclusions
The updated Lung-molGPA defined in the present study was associated with improved prognostic ability over the RTOG RPA and the original DS-GPA by incorporating the effect of EGFR and ALK gene alterations on survival in patients with NSCLC and brain metastases. The Lung-molGPA is a user-friendly tool that may facilitate clinical decision making and better design and stratification for future clinical trials in this heterogeneous patient population. Historically, the prognosis for patients with brain metastases was thought to be uniformly poor, which led to a purely palliative approach to treating the many patients diagnosed with this very common neurologic complication of cancer. In addition, brain metastases were previously considered a homogeneous disease, despite the myriad of tumors that could potentially spread to the brain and the observed variability in response to local and systemic therapies. Because physicians believed that the vast majority of patients with brain metastases would have uniformly poor outcomes, they adopted whole-brain radiation therapy (WBRT) as the standard of care: it is easy to administer, widely available, and effective at providing palliation.
As our understanding of brain metastases has evolved, however, interest in clinical trials has intensified; focus on optimizing care has sharpened; acceptance of treatment options such as stereotactic radiosurgery (SRS) has increased; and the need for robust prognostic indices has become evident. One of the first prognostic indices was the Recursive Partitioning Analysis, a system that was based on data from Radiation Therapy Oncology Group (RTOG) trials 1 and that stratified brain metastases into 3 distinct groups using patient age, Karnofsky Performance Status (KPS), primary tumor status, and extracranial disease. The Graded Prognostic Assessment (GPA), 2 which incorporated the number of brain metastases rather than primary tumor status and further subdivided age into 3 categories, allowed for a less subjective and more quantitative prognostic index than the RTOG Recursive Partitioning Analysis. In a later refinement, the Disease-Specific GPA (DS-GPA) 3 further stratified patients with brain metastases by primary site and highlighted the differences among the various tumors that metastasize to the brain. 3 Nonetheless, the need for even better prognostic tools was highlighted by Kondziolka et al, 4 who estimated survival using prognostic scores in combination with clinical, radiologic, and primary tumor data in 150 patients with brain metastases. The researchers then surveyed a group of expert neurosurgeons, radiation oncologists, and medical neurooncologists regarding prognosis and found considerable inaccuracy among the predictions: 45% and 18% of surveyed clinician predictions inaccurately estimated patient survival by more than 6 months and more than 12 months, respectively. In this issue of JAMA Oncology, Sperduto and colleagues 5 report on an updated DS-GPA for lung cancer with brain metastases by incorporating genetic and molecular information, the Lung-molGPA. Unlike the previous DS-GPA for lung cancer, which included patient data from 1985 through 2005, this study incorporates data from a contemporary, retrospective multi-institutional database of 2186 patients from 2006 through 2014. Two new factors (EGFR mutation and ALK rearrangement in adenocarcinoma) combined with the 4 known significant factors (patient age, number of brain metastases, extracranial disease, and KPS) from the previous Lung DS-GPA further stratified patients into 4 groups with median survival times now ranging from 3.0 to 46.8 months.
The most favorable prognostic factors were KPS scores between 90 and 100, absence of extracranial metastases, and EGFR or ALK positivity in adenocarcinoma. Patients with the highest GPA scores of 3.5 to 4.0 represented only 4% of all patients. The overall median survival for the group increased from 7 months at the time of the DS-GPA design to 12 months in the contemporary data. 
